










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































(n=22)	 AM	 PM	 EVE	 p	
Plasma	Co	 10,	11.3	(4.8-20)		 10,	11.4	(4.7-22)	 10,	9(4.7-22)	 0.66	
Plasma	Cr	 2,	1.7	(0.69-7.1)	 2.1,	1.7	(0.75-7.1)	 2.3,	1.9	(0.93-7.2)	 0.03*	
Urine	Co	 41,	47		(6.1-175)	 53,	38	(5.6-209)	 35,	31	(9-149)	 0.19	


























































































































































































































































































































































































































































































































































































The	 input	of	 the	gene	of	 interest,	was	normalised	by	dividing	 the	gene	of	 interest	by	
the	 geometric	 mean	 of	 Top1	 and	 Cyc1	 since	 Normfinder	 software	
(http://moma.dk/normfinder-software)	 analysis	 revealed	 that	 these	 two	genes	were	
contamination	free	and	demonstrated	the	least	degree	of	change.	The	geometric	mean	
is	 defined	 as	 the	 nth	square	 root	 (n	 is	 equal	 to	 the	 number	 of	 samples)	 of	 the	 total	
values	of	each	sample	multiplied	by	each	other	i.e.	
	












































































































































































































































Ingenuity	Canonical	Pathway		 p	value	 Ratio	 Molecules	
	 	 	 	
Inhibition	of	Matrix	Metalloproteases	 0.0004***	 0.05	 TIMP3,MMP12	
Leukocyte	Extravasation	Signalling	 0.0100**	 0.01	 TIMP3,MMP12	
Oncostatin	M	Signalling	 0.0280*	 0.03	 TIMP3	
Primary	Immunodeficiency	Signalling	 0.0398*	 0.02	 IGLL1/IGLL5	




Bladder	Cancer	Signalling	 0.0660	 0.01	 MMP12	
HIF1	Signalling	 0.0776	 0.01	 MMP12	
Rac	Signalling	 0.0776	 0.01	 CYFIP2	
IL-6	Signalling	 0.0870	 0.01	 TNFAIP6	
Mitochondrial	Dysfunction	 0.1250	 0.01	 NDUFA4L2	
Granulocyte	Adhesion	and	Diapedesis	 0.1300	 0.01	 MMP12	
Agranulocyte	Adhesion	and	Diapedesis	 0.1380	 0.01	 MMP12	
Actin	Cytoskeleton	Signalling	 0.1570	 0.00	 CYFIP2	










































Ingenuity)Canonical)Pathways p)value Ratio Molecules
ErbB%Signaling 0.0007762 0.0465 FOS,FOXO1,BTC,HBEGF
Atherosclerosis%Signaling 0.0029512 0.0325 MMP3,CD36,PLA2G7,CLU
Neuregulin%Signaling 0.0087096 0.0341 BTC,HBEGF,ERRFI1
Oncostatin%M%Signaling 0.0114815 0.0588 TIMP3,MMP3
CDK5%Signaling 0.0120226 0.0303 FOSB,EGR1,ADCY3
Role%of%Tissue%Factor%in%Cancer 0.0158489 0.0273 EGR1,ITGAV,HBEGF
FXR/RXR%Activation 0.0234423 0.0236 FOXO1,CYP27A1,CLU
GNRH%Signaling 0.0239883 0.0233 FOS,EGR1,ADCY3
UDPUNUacetylUDUglucosamine%Biosynthesis%II 0.0281838 0.167 GFPT2
CXCR4%Signaling 0.0371535 0.0197 FOS,EGR1,ADCY3
EndothelinU1%Signaling 0.0501187 0.0174 FOS,ADCY3,PLA2G7
Granulocyte%Adhesion%and%Diapedesis 0.0537032 0.0169 MMP3,MMP12,CXCL6
Role%of%ILU17A%in%Psoriasis 0.060256 0.0769 CXCL6
Bile%Acid%Biosynthesis,%Neutral%Pathway 0.060256 0.0769 CYP27A1
Pyrimidine%Deoxyribonucleotides%De%Novo%Biosynthesis% 0.1004616 0.0455 AK1
ILU6%Signaling 0.1071519 0.0172 FOS,TNFAIP6
ILU17A%Signaling%in%Gastric%Cells 0.1135011 0.04 FOS
LXR/RXR%Activation 0.1148154 0.0165 CD36,CLU
Pyrimidine%Ribonucleotides%Interconversion 0.121899 0.037 AK1
TNFR2%Signaling 0.1303167 0.0345 FOS
Pyrimidine%Ribonucleotides%De%Novo%Biosynthesis 0.1303167 0.0345 AK1
ILU12%Signaling%and%Production%in%Macrophages 0.1370882 0.0148 FOS,CLU
Aryl%Hydrocarbon%Receptor%Signaling 0.1455459 0.0143 FOS,NQO1
Complement%System 0.1468926 0.0303 CFI
Inhibition%of%Angiogenesis%by%TSP1 0.151008 0.0294 CD36
Cell%Cycle%Regulation%by%BTG%Family%Proteins 0.1552387 0.0286 BTG2
ILU17A%Signaling%in%Fibroblasts 0.1552387 0.0286 FOS
Hepatic%Cholestasis 0.18281 0.0123 CYP27A1,ADCY3
iNOS%Signaling 0.1909853 0.0227 FOS
Role%of%NFAT%in%Regulation%of%the%Immune%Response 0.1981527 0.0117 RCAN1,FOS
RAR%Activation 0.2070141 0.0114 FOS,ADCY3
ILU10%Signaling 0.2792544 0.0147 FOS
LPS/ILU1%Mediated%Inhibition%of%RXR%Function 0.2831392 0.00913 HS3ST2,FABP5
LPSUstimulated%MAPK%Signaling 0.2964831 0.0137 FOS
TollUlike%Receptor%Signaling 0.2999163 0.0135 FOS



















Ingenuity)Canonical)Pathways p)value Ratio Molecules
Atherosclerosis+Signaling 0.00081283 0.0325 MMP3,CD36,PLA2G7,CLU
ErbB+Signaling 0.0030903 0.0349 FOS,BTC,HBEGF
Neuregulin+Signaling 0.00331131 0.0341 BTC,HBEGF,ERRFI1
LPS/ILO1+Mediated+Inhibition+of+RXR+Function 0.00645654 0.0183 ALDH1A3,HS3ST2,FABP5,LBP
LXR/RXR+Activation 0.00812831 0.0248 CD36,LBP,CLU
iNOS+Signaling 0.00977237 0.0455 FOS,LBP
UDPONOacetylODOglucosamine+Biosynthesis+II 0.01995262 0.167 GFPT2
ILO10+Signaling 0.02238721 0.0294 FOS,LBP
LPSOstimulated+MAPK+Signaling 0.02570396 0.0274 FOS,LBP
TollOlike+Receptor+Signaling 0.02630268 0.027 FOS,LBP
Role+of+ILO17A+in+Psoriasis 0.04365158 0.0769 CXCL6
Bile+Acid+Biosynthesis,+Neutral+Pathway 0.04365158 0.0769 CYP27A1
Histamine+Degradation 0.04365158 0.0769 ALDH1A3
CDK5+Signaling 0.04466836 0.0202 FOSB,EGR1
Fatty+Acid+Î±Ooxidation 0.05248075 0.0625 ALDH1A3
Oxidative+Ethanol+Degradation+III 0.05248075 0.0625 ALDH1A3
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? Molecular	 Biology	 reagents,	
RNA/DNA	prep,	enzymes	
? Histology	reagents,	microscopy	

































? 4	 symptomatic	 with	 abnormal	
MRI	awaiting	revision	
	






















INITIAL	 VISIT	 =	 £4,928.52	 (£	 410.71	
per	patient)	
	
















? £	 190.80	 –	 Endnote	 X5	
bibliographic	software	


















2. Use	 of	 biomarkers	 including	 levels	 of	 cobalt	 and	 chromium	 species	 in	 blood	
and	urine	as	a	predictor	of	severity	of	disease.	
3. The	 use	 of	 Liquid	 Chromatography-Tandem	 Mass	 Spectrometry	 to	






within	 the	 hip	 joint	 at	 revision	 surgery	 for	metallosis	 and	 compare	 this	with	
archived	tissue.	
7. The	 cellular	 and	 cytokine/chemokine/growth	 factor	 expression	 patterns	 in	
















Trauma	 &	 Orthopaedic	 Surgery,	 Primary	 &	 Revision	 Hip	
Arthroplasty	
Are	 there	 any	 other	




Is	 there	 a	 conflict	 of	




The	 principal	 investigator	 (or	 the	 respective	 institution)	 is	 obliged	 to	 agree	 to	 the	
terms	 and	 conditions	 of	 Orthopaedic	 Research	 UK	 standard	 academic	 contract	 and	
return	a	 signed	 copy	of	 the	 contract,	 no	 later	 than	3	months	after	 stage	4.	Contracts	























for	 primary	 and	 revision	 hip	 surgery	 with	 significant	 experience	 of	 revisions	 for	
metallosis	in	a	variety	of	implants.	
Despite	 initial	 promise	 of	 decreased	wear	 rates	 and	 increasing	 suitability	 for	 use	 in	
younger	more	active	patients,	concerns	remain	about	potential	adverse	consequences	
of	 MoM	 bearing	 surfaces	 in	 terms	 of	 aseptic	 loosening	 and	 pain	 secondary	 to	 soft	
tissue	reaction	to	metal	debris.		




conclusively	 demonstrated,	 but	 may	 represent	 a	 delayed	 type	 IV	 (ALVAL)	
hypersensitivity	 reaction	 with	 subsequent	 effect	 on	 local	 cell	 populations	 in	
susceptible	individuals,	giving	rise	to	painful	soft	tissue	mass	or	pseudotumour	as	well	
as	osteolysis	and	loosening	68.		
It	 is	 suggested	 that	 soft	 tissue	 reactions	may	 be	 the	 result	 of	 increased	wear	 that	 is	
directly	correlated	with	elevation	of	cobalt	(Co)	and	chromium	(Cr)	in	vivo	where	the	




and	 revision	 surgery	 (osteolysis	 vs.	 well-fixed).	 	 Tissue	 is	 stored	 in	 RNA	 Later	
immediately	 post-surgery,	 prior	 to	 downstream	RNA	 purification	 and	 analysis	 using	











metal	 ion	 levels	 and	 radiological	 findings	 using	 Metal	 Artefact	 Reduction	 Sequence	
(MARS)	MRI	scan.	
MARS	MRI,	developed	at	our	institution	reduces	artefact	and	increase	the	conspicuity	









raised	 (p=0.09)	 in	 bilateral	 THRs	 (5.3ppb)	 than	 unilateral	 THRs	 (4.22ppb).	 In	
unilateral	THRs	there	were	higher	mean	values	 for	 females	 for	both	Co	and	Cr	metal	
ion	 levels.	 The	mean	 value	 of	 Cr	 for	 females	was	 4.95ppb	 versus	 3.81ppb	 for	males	
(p=0.008)*.	 The	 mean	 value	 for	 Co	 ions	 for	 females	 was	 9.69ppb,	 and	 for	 males	
8.66ppb	(p=0.254).	





impairment.	 Levels	 of	metal	 ions	 are	 higher	 in	 females	with	 unilateral	 implants.	 No	
association	between	abnormal	MRI	and	metal	ion	levels	was	demonstrated.	
Timing	 and	 indications	 for	 revision	 remain	 challenging	 clinical	 problems	 since	 the	
natural	 history	 of	 metallosis	 remains	 unknown.	 Radiological	 appearances	 of	 MoM	





with	MOM	THRs	who	had	not	undergone	 revision	 surgery	and	who	had	at	 least	 two	
serial	MARS	MRI	examinations.			
Patients	were	 identified	 from	a	database	and	all	MRI	examinations	were	reported	by	




range:	 3.9	 to	 6.7).	 The	 time	 between	 surgery	 and	 all	 MRIs	 ranged	 from	 0.8	 to	 13.4	
years.	Grades	for	all	MRIs	were:	A	59%	(131),	B	2%	(5),	C1	15%	(34),	C2	16%	(35)	and	
C3	8%	(18).		







revision	 have	 normal	 MRI	 examinations.	 	 Progression	 from	 normal	 to	 abnormal,	 or	













undertaken	 throughout	 the	 course	 of	 the	 MD.	 Data	 in	 terms	 of	 metal	 ion	 levels,	
radiological	 MRI	 gradings,	 patient	 outcome	 measures	 (Oxford	 scores	 and	 EQ-5D	










Hospital	 (NNUH),	 with	 the	 laboratory	 work	 being	 carried	 out	 at	 UEA	 School	 of	
Biological	Sciences.	Laboratory	studies	will	commence	August	2012	and	continue	for	a	
period	of	one	year.		
Informed	consent	will	 be	obtained	 from	patients	 attending	 specialist	MoM	 follow	up	
clinics.	 Patients	 in	 the	 Ultima	 TPS	 follow-up	 group	 will	 have	 a	 patient	 information	
sheet	 posted	 2	 to	 3	 weeks	 before	 their	 routine	 follow-up	 clinic.	 Those	 willing	 to	
participate	will	then	consented	and	the	sample	taken.	
Collection	of	samples	of	capsule,	femoral	and	acetabular	membrane,	muscle	and	bone	
from	primary	 joints,	 and	 revision	hip	arthroplasty	 in	28mm	head	 (Ultima)	and	 large	
head	 (ASR)	 MoM	 articulations	 for	 adverse	 reactions	 to	 metal	 debris	 will	 allow	 the	
investigator	to	compare	and	contrast	cytokine	and	cellular	components.	Tissue	will	be	
stored	in	RNA	Later	immediately	post-surgery,	prior	to	downstream	RNA	purification	
and	 analysis	 using	 qRT-PCR.	 We	 have	 already	 established	 permission	 and	
infrastructure	 for	 a	 tissue	 bank	 of	 samples	 collected	 from	 MoM	 revisions,	 revision	
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surgery	 of	 other	 bearing	 surfaces	 and	 primary	 THRs	 to	 act	 as	 comparators	 for	 our	
work.		
WP2	DELIVERABLE:	
? Knowledge	 of	 cellular	 and	 cytokine/chemokine/growth	 factor	 expression	




WORK	PACKAGE	3	 (WP3):	Feasibility	 study	 into	Diurnal	Variation	 in	Metal	 Ion	
Levels	
There	 is	 no	 evidence	 in	 the	 literature	 examining	 the	 diurnal	 variation	 in	 metal	 ion	
levels	detectable	in	blood	and	urine.	There	is	no	consensus	of	opinion	as	to	whether	an	
isolated	elevated	metal	ion	level	is	indicative	or	predictive	of	a	pathological	state,	or	if	
circulating	 levels	of	metal	 ion	 levels	 fluctuate	with	 activity	 in	 a	 fashion	analogous	 to	
blood	glucose	levels.	I	wish	to	establish	a	feasibility	study	recruiting	participants	from	
our	 cohort	 of	 650	 Ultima	 TPS	 hips	 with	 symptomatic	 hips	 with	 a	 normal	 MRI,	
symptomatic	hip	with	abnormal	MRI	and	asymptomatic	hips	with	a	normal	MRI.	These	
patients	will	be	seen	 in	our	research	 trials	unit	and	have	blood	and	urine	specimens	





? Knowledge	 of	 variance	 of	 blood	 ion	 level	 and	 how	 this	 correlates	 with	 MRI	
grading	in	order	to	inform	MHRA	guidance.	
	




revision	 is	unknown.	 	The	 study	will	describe	 the	medium	 to	 long-term	 follow	up	of	
patients	with	MOM	THR	with	MRI.	




classified	 according	 to	 a	 grading	 system	 developed	 in	 Norwich	 as:	 A	 (normal),	 B	
(Infection),	C1	(Mild	MOM	disease),	C2	(Moderate	disease),	and	C3	(Severe	disease).		
WP4	DELIVERABLE:	





A	 review	 of	 the	 literature	 has	 established	 that	 there	 is	 no	 validated	 system	 for	
macroscopic	 classification	 of	 metal	 on	 metal	 disease	 observed	 intraoperatively.	 We	
regularly	undertake	revisions	of	MoM	hips	in	our	cohort	of	650	Ultima	TPS	as	well	as	
revising	a	significant	number	of	other	MoM	implant	types.	We	would	seek	to	develop	a	
simple	 grading	 tool	 for	 assessment	 of	 extent	 of	 soft	 tissue	 destruction,	 bony	
















Research/clinical/technical	 support,	 laboratory	 space,	 equipment	 and	
additional	funding	if	any	(strictly	maximum	250	words)	
	
Norwich	 Medical	 School	 provides	 a	 complete	 set	 of	 facilities	 and	 an	 educational	
programme	 for	 doctoral	 students	 including	 an	 800,00	 volume	 library	 of	 books	 and	
journals,	 a	 large	 range	 of	 electronic	 resources	 including	 major	 bibliographic	 and	
citation	databases	as	well	as	full	text	journal	archives.		
The	 Institute	 of	 Orthopaedics	 at	 the	 Norfolk	 &	 Norwich	 University	 Hospital	 is	 a	
dedicated	 research	 facility	 with	 ample	 office	 space,	 full	 time	 research	 practitioners,	
and	 administrative	 support.	 We	 have	 IT	 support	 for	 multiple	 workstations	 running	
patient	 electronic	 medical	 records,	 clinical	 information	 systems,	 high-resolution	
Picture	 Archiving	 and	 Communication	 software,	 as	 well	 as	 standard	 office	 and	
statistical	packages.	
The	NNUH	in	conjunction	with	UEA	has	a	Clinical	Research	and	Trials	Unit	staffed	by	





The	Clark	 laboratory	 is	 housed	 in	 the	Biomedical	Research	Centre,	 a	 state-of-the-art	
facility	for	molecular	research.			All	expertise	and	equipment	is	available	to	support	the	
gene	 expression	 studies	 outlined	 above.	 There	 are	 excellent	mammalian	 cell	 culture	
facilities	and	a	wide	range	of	multi-user	equipment	including	ABI	7500	and	7700	Real-









levels	 of	 corrosion	 from	 the	 implant	 stem.	 The	 reasons	 for	 this	 are	 unclear.	 Recent	
work	indicates	that	unlike	 in	 large	diameter	head	implants	 it	 is	not	the	MoM	bearing	
which	 is	 responsible.	 It	 could	 be	 galvanic	 corrosion,	 and	 work	 in	 Leeds	 has	 noted	
different	 levels	 of	 acidity	 from	 different	 bone	 cements.	 Greater	 knowledge	 has	
furthered	the	complexity.		
Norwich	 was	 the	 dominant	 site	 for	 this	 implant	 and	 the	 problems	 have	 not	 been	
reported	elsewhere.	Furthermore	 the	unusual	 feature	 is	 that	a	significant	proportion	
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of	 these	 patients	 have	 pain	 but	 normal	 X-rays.	 New	 MRI	 techniques	 developed	 in	
Norwich	allow	us	to	see	abnormalities	otherwise	not	visible.		
Analysis	of	cells,	 tissue,	bodily	 fluids,	and	 imaging	may	 identify	patients	at	risk,	 from	
those	 who	 are	 not.	 Although	 our	 population	 is	 unique,	 it	 transpires	 that	 all	 MoM	
implants	risk	the	problems	of	metallosis.	This	research	will	provide	valuable	 insights	
into	 the	 aetiology	of	metallosis	 in	 the	Ultima	 cohort	 and	 in	MoM	hip	 articulations	 in	









replacement	 in	 the	 presence	 of	 normal	 plain	 radiographs.	 JBJS	 Br	 2010;	
92(11):1501-8	
Back	DL,	Young	DA,	Shimmin	AJ.	How	do	serum	cobalt	and	chromium	levels	change	








metal-on-metal	 total	 hip	 arthroplasty.	 Arch	Orthop	Trauma	 Surg	 	 2010;	 130:	
1447-1450.	
Mabilleau	 G,	 Kwon	 Y,	 Pandit	 H,	 Murray	 DW,	 Sakobar	 A.	 Metal-on-metal	 hip	
resurfacing	arthroplasty:	A	 review	of	periprosthetic	biological	 reactions.	Acta	
Orthopaedica	2008;	79:	734-747.	
Kwon	 Y,	 Ostlere	 SJ,	 McLardy-Smith	 P	 et	 al.	 Asymptomatic	 pseudotumors	 after	





Johnston	 P,	 Chojnowski	 AJ,	 Davidson	 RK,	 Riley	 GP,	 Donell	 ST	 and	 Clark	 IM	 A	






















































cobalt-	 chromium-molybdenum	 (CoCrMo)	 for	 their	 hardness.	 Wear	 particles	
generated	 by	 MOM	 hips	 in	 simulators	 are	 smaller	 than	 particles	 generated	 by	
metal-on-polyethylene	(MoP)	articulations,	but	MOM	hips	release	at	least	three	times	
more	 cobalt	 and	 chromium	 ions	 than	 MoP	 THRs.	 Wear	 particles	 and	 metallic	
by-products	are	 readily	distributed	 throughout	 the	body	by	 the	blood	and	 lymphatic	
vessels.	Much	attention	 is	 being	 given	 to	 the	 systemic	distribution	of	metal	 particles	








Norwich	 was	 the	 dominant	 site	 for	 this	 implant	 and	 the	 problems	 have	 not	 been	
reported	 elsewhere.	 Furthermore	 the	unusual	 feature	was	 that	 a	 third	had	pain,	 but	
	 140	
normal	 X-rays.	 New	 MRI	 techniques	 developed	 in	 Norwich	 allow	 us	 to	 see	
abnormalities	otherwise	not	visible.	
Analysis	of	cells,	 tissue,	bodily	 fluids,	and	 imaging	may	 identify	patients	at	risk,	 from	












metallosis.	 We	 aim	 to	 characterise	 how	 these	 implants	 affect	 cells	 in	 surrounding	
tissues	and	which	patients	may	have	an	increased	susceptibility	to	metal	reactions.		

















I	 am	 an	 orthopaedic	 trainee	 who	 has	 completed	 core	 surgical	 training.	 I	 am	
undertaking	 an	 MD	 to	 consolidate	 previous	 basic	 science	 research	 experience	 and	








Dear Mr Darren Ebreo,  Our New Ref: 489 
Title: Role of Metal Ions in Metal on Metal Hip Arthroplasty 
  
Thank you for submitting your proposal to Orthopaedic Research UK 
(ORUK). In this call a total of 80 research proposals were received by ORUK 
and based on the budget that we were allocated for the 3rd call 2011, we were 
in a position to offer funding to the top 5 proposals which received the highest 
votes by our internal review committee. 
  
I am pleased to inform you that the Trustees have agreed supporting the above 
MD research project by awarding £59,924.33 over 24 months. 
  
A standard academic agreement will be sent to the University of East Anglia 
for countersigning. Please let me know the name of the person who deals with 
your research grants at the University. 
  
On behalf of ORUK, I would like to take this opportunity to congratulate you 




Dr Arash Angadji 
Project Manager 
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Furlong House 
10a Chandos Street 
London W1G 9DQ 
  
T. 020 7637 5789 
F. 020 7636 4936 













































We	 have	 a	 well-defined	 cohort	 of	 patients	 with	 an	 Ultima	 TPS	 metal	 on	 metal	
(MoM)	 total	 hip	 replacement	 (THR)	 with	 a	 catastrophic	 failure	 rate	 for	 which	 a	
series	of	ethically	approved	studies	have	been	undertaken.	
	
MoM	 THR	 is	 currently	 of	 national	 concern	 with	 the	 Medicines	 and	 Healthcare	
products	 Regulatory	 Agency	 (MHRA)	 guidelines	 recommending	 scans	 and	
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by	 the	manufacturer	 and	 is	 the	 subject	 of	 a	Medicines	 and	 Healthcare	 products	





younger	 active	 patients,	 concerns	 remain	 about	 potential	 consequences	 of	MoM	
bearing	 surfaces	 in	 terms	 of	 aseptic	 loosening	 and	 pain	 secondary	 to	 soft	 tissue	
reaction	to	metal	debris.		
	
Elevated	 circulating	 levels	 of	 metal	 ions	 following	 MoM	 THR	 or	 resurfacing	
arthroplasty	are	not	uncommon	125	 126	 127	with	metal	 ion	 levels	 reaching	a	 steady	
state	 approximately	 1	 year	 following	 implantation	 128.	 The	 biological	 pathways	
leading	to	adverse	periprosthetic	soft	tissue	reactions	associated	with	metal	debris	
have	 yet	 to	 be	 demonstrated,	 but	 may	 represent	 a	 delayed	 type	 IV	 (ALVAL)	

















































































































occasions	 and	 be	 required	 to	 donate	 blood	 and	 urine	 specimens	 for	 analysis	 of	
Cobalt	 and	 Chromium	 levels	 at	 a	 specialist	 accredited	 reference	 laboratory	 for	
trace	metal	analysis	via	Inductively	Coupled	Plasma	Mass	Spectrometry.	Protocols	


















































































































































































































































































































































































	 ng/μl	 260:280	 260:230	
2	curls	 40	 2.12	 1.11	
4	curls	 65	 2.05	 1.4	
















07TB0043	 131.5	 2.09	 1.27	
08TB0059	 186.6	 2.08	 1.42	
09TB0029	 17.8	 2.15	 0.95	
10TB0003	 30.3	 2.11	 1.51	
11TB0004	 65.2	 2.09	 0.74	












Lane	 Sample	 RNA	ng/µl	 Ratio	(28S/18S)	 RQI	
L	 Ladder		 160	 	 	
1	 07TB0043	 136.25	 1.19	 7.6	
2	 08TB0059	 143.19	 1.41	 7.9	
3	 09TB0029	 8.41	 1.04	 N/A	
4	 10TB0003	 1.95	 1.74	 N/A	
5	 11TB0004	 73.67	 1.24	 8.8	



























































































Minimum information about a microarray experiment (MIAME) 
Background information:  A brief description of the experiment 
(e.g., the abstract from the related publication, links to the 




with	 increased	 mobility	 on	 longevity	 	 compared	 to	 the	 metal-on-	 polyethylene	 (MoP)	 implants.	
However,	there	has	been	a	high	rate	of	failure,	adverse	reactions	to	the	MoM	bearing	surfaces	have	
resulted	in	implant	failure,	pain	and	the	development	of	inflammatory	masses.	Adverse	reactions	to	
metal	debris	 (ARMD)	 is	an	emerging	cause	of	major	morbidity	 in	hip	arthroplasty	that	significantly	




Primary	 total	 hip	 replacements.	 With	 this	 information	 we	 can	 examine	 how	 reactions	 to	
polyethylene	 and	 metal	 debris	 might	 trigger	 the	 activation	 of	 biological	 cascades	 involved	 with	





Experiments purpose and justifications: The goal of the experiment – 





Experimental factors and keywords:  For example, time course, cell 
type comparison, the parameters or conditions tested, such as time, 
dose, or genetic variation:  
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Experimental design - relationships between samples, treatments, 
(e.g., a diagram or table showing experimental factors under study 
























Type of chips required to use: Illumina	Human	HT-12	v4	Expression	Bead	Chip	
 
The origin of each biological sample:  (e.g., name of the organism, 
the provider of the sample) and its characteristics (e.g., gender, 
age, and developmental stage, strain, disease state): 	
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Specimen	ID	 Tissue	Type	 Gender	 Disease	process	
P	A	 Human	Hip	Capsule	 Female	 Primary	THR	for		
Osteoarthritis	
P	B	 Human	Hip	Capsule	 Female	 Primary	THR	for	
Osteoarthritis	
P	C	 Human	Hip	Capsule	 Female	 Primary	THR	for	
Osteoarthritis	
P	D	 Human	Hip	Capsule	 Female	 Primary	THR	
Osteoarthritis	
MOP	A		 Human	Hip	Capsule	 Male	 MoP	Revision	for	
Aseptic	Loosening	
MOP	B	 Human	Hip	Capsule	 Female	 MoP	Revision	for	
Aseptic	Loosening	
MOP	C	 Human	Hip	Capsule	 Male	 MoP	Revision	for	
Aseptic	Loosening	
MOP	D	 Human	Hip	Capsule	 Female	 MoP	Revision	for	
Aseptic	Loosening	
MOM	A		 Human	Hip	Capsule	 Male	 MoM	Revision	for	
ARMD	[Ultima	MoM	
THR]	
MOM	B		 Human	Hip	Capsule	 Female	 MoM	Revision	for	
ARMD	[Ultima	MoM	
THR]	
MOM	C	 Human	Hip	Capsule	 Male	 MoM	Revision	for	
ARMD	[Ultima	MoM	
THR]	









Genetic modifications/characteristics: N/A 
 
 
Ref. to clinical data/information: 
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Developmental stage: N/A 
 
Manipulation of biological samples and protocols used (e.g., growth 














Tissue/cell harvesting methods/ Separation technique:  
	




Strain or line/ Genetic Variation: N/A 
 
Growth condition: N/A 
 
Technical protocols for preparing the hybridization extract (e.g., 








RNA source and extraction methods: 	
 
RNA Amplification used if any: N/A 
 









We	 the	 above	 confirm	 that	 results	 obtained	 using	 the	 microarray	 facility	 will	 be	 fully	 and	


























The protein encoded by this gene is the fourth major glycoprotein of the platelet surface and serves as a receptor for 
thrombospondin in platelets and various cell lines. Since thrombospondins are widely distributed proteins involved in a 
variety of adhesive processes, this protein may have important functions as a cell adhesion molecule. It binds to 
collagen, thrombospondin, anionic phospholipids and oxidized LDL. It directly mediates cytoadherence of Plasmodium 
falciparum parasitized erythrocytes and it binds long chain fatty acids and may function in the transport and/or as a 






Secreted by activated human macrophages and is markedly elevated in plasma of Gaucher disease patients. The 





Cytochrome P450, family 27, subfamily A, polypeptide 1 
 
Encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are 
monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids 





Heparan sulfate (glucosamine) 3-O-sulfotransferase 2 
 
The enzyme encoded by this gene is a member of the heparan sulfate biosynthetic enzyme family. It is a type II 
integral membrane protein and possesses heparan sulfate glucosaminyl 3-O-sulfotransferase activity. This gene is 




CAMPATH-1 Antigen/Cluster of Differentiation 52 
 
CD52 is present on the surface of mature lymphocytes, but not on the stem cells from which these lymphocytes were 






 Gene$ Function p$value!
PLA2G7$
Phospholipase A2.  
The protein encoded by this gene is a secreted enzyme that catalyzes the degradation of platelet-activating factor to 




Aldehyde dehydrogenase 1 family, member A3. Gene encodes an aldehyde dehydrogenase enzyme that uses 
retinal as a substrate. Mutations in this gene have been associated with microphthalmia, isolated 8, and expression 




Matrix Metallopeptidase 12.  
 
Proteins of the matrix metalloproteinase (MMP) family are involved in the breakdown of extracellular matrix in normal 
physiological processes, such as embryonic development, reproduction, and tissue remodeling, as well as in disease 
processes, such as arthritis and metastasis. Most MMP's are secreted as inactive proproteins which are activated 
when cleaved by extracellular proteinases. It is thought that the protein encoded by this gene is cleaved at both ends to 
yield the active enzyme, but this processing has not been fully described. The enzyme degrades soluble and insoluble 





Granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 1).  
 
Cytolytic T lymphocytes (CTL) and natural killer (NK) cells share the remarkable ability to recognize, bind, and lyse 
specific target cells. They are thought to protect their host by lysing cells bearing on their surface 'nonself' antigens, 
usually peptides or proteins resulting from infection by intracellular pathogens. The protein encoded by this gene is 





Ectonucleotide pyrophosphatase/phosphodiesterase 1.  
 
The encoded protein is a type II transmembrane glycoprotein comprising two identical disulfide-bonded subunits. This 
protein has broad specificity and cleaves a variety of substrates, including phosphodiester bonds of nucleotides and 
nucleotide sugars and pyrophosphate bonds of nucleotides and nucleotide sugars. This protein may function to 
hydrolyze nucleoside 5' triphosphates to their corresponding monophosphates and may also hydrolyze diadenosine 
polyphosphates. Mutations in this gene have been associated with 'idiopathic' infantile arterial calcification, ossification 






 Gene$ Function p$value!
FOSB$
FBJ murine osteosarcoma viral oncogene homolog B 
 
The Fos gene family consists of 4 members: FOS, FOSB, FOSL1, and FOSL2. These genes encode leucine zipper 
proteins that can dimerize with proteins of the JUN family, thereby forming the transcription factor complex AP-1. As 
such, the FOS proteins have been implicated as regulators of cell proliferation, differentiation, and transformation. 




FBJ murine osteosarcoma viral oncogene homolog.  
 
Genes encode leucine zipper proteins that can dimerize with proteins of the JUN family, thereby forming the 
transcription factor complex AP-1. As such, the FOS proteins have been implicated as regulators of cell proliferation, 
differentiation, and transformation. Alternatively spliced transcript variants encoding different isoforms have been found 




Collagen, type XXII, alpha 1.  
 
The COL22A1 gene on human chromosome 8q24.2 encodes a collagen that structurally belongs to the FACIT protein 
family (fibril-associated collagens with interrupted triple helices). Collagen XXII exhibits a striking restricted localization 
at tissue junctions such as the myotendinous junction in skeletal and heart muscle, the articular cartilage-synovial fluid 
junction, or the border between the anagen hair follicle and the dermis in the skin. It is deposited in the basement 
membrane zone of the myotendinous junction and the hair follicle and associated with the extrafibrillar matrix in 
cartilage. In situ hybridization of myotendinous junctions revealed that muscle cells produce collagen XXII, and 
functional tests demonstrated that collagen XXII acts as a cell adhesion ligand for skin epithelial cells and fibroblasts. 





Early growth response 1. 
  
Protein encoded by this gene belongs to the EGR family of C2H2-type zinc-finger proteins. It is a nuclear protein and 
functions as a transcriptional regulator. The products of target genes it activates are required for differentitation and 








 Gene$ Function p$value!
NR4A2$
Nuclear receptor subfamily 4, group A, member 2 
 
Gene encodes a member of the steroid-thyroid hormone-retinoid receptor superfamily. The encoded protein may act as 
a transcription factor. Mutations in this gene have been associated with disorders related to dopaminergic dysfunction, 








The mineralized portions of teeth, the dentin and enamel, are formed by mesenchyme-derived odontoblasts and 





Chitinase 3-like 2 
The protein encoded by this gene is similar to bacterial chitinases but lacks chitinase activity. The encoded protein is 











Proteins of the matrix metalloproteinase (MMP) family are involved in the breakdown of extracellular matrix in normal 
physiological processes, such as embryonic development, reproduction, and tissue remodeling, as well as in disease 
processes, such as arthritis and metastasis. Most MMP's are secreted as inactive proproteins which are activated 
when cleaved by extracellular proteinases. This gene encodes an enzyme which degrades fibronectin, laminin, 
collagens III, IV, IX, and X, and cartilage proteoglycans. The enzyme is thought to be involved in wound repair, 







 Gene$ Function$ p$value!
GJB2$
Gap junction protein, beta 2, 26kDa 
 
This gene encodes a member of the gap junction protein family. The gap junctions were first characterized by electron 
microscopy as regionally specialized structures on plasma membranes of contacting adherent cells. These structures 




Tumor necrosis factor, alpha-induced protein 6 
 
The protein encoded by this gene is a secretory protein that contains a hyaluronan-binding domain, and thus is a 
member of the hyaluronan-binding protein family. The hyaluronan-binding domain is known to be involved in 
extracellular matrix stability and cell migration. This protein has been shown to form a stable complex with inter-alpha-
inhibitor (I alpha I), and thus enhance the serine protease inhibitory activity of I alpha I, which is important in the 
protease network associated with inflammation. This gene can be induced by proinflammatory cytokines such as tumor 
necrosis factor alpha and interleukin-1. Enhanced levels of this protein are found in the synovial fluid of patients with 




Complement factor I 
 
This gene encodes a serine proteinase that is essential for regulating the complement cascade. The encoded 
preproprotein is cleaved to produce both heavy and light chains, which are linked by disulfide bonds to form a 
heterodimeric glycoprotein. This heterodimer can cleave and inactivate the complement components C4b and C3b, 
and it prevents the assembly of the C3 and C5 convertase enzymes. Defects in this gene cause complement factor I 
deficiency, an autosomal recessive disease associated with a susceptibility to pyogenic infections. Mutations in this 
gene have been associated with a predisposition to atypical hemolytic uraemic syndrome, a disease characterized by 
acute renal failure, microangiopathic hemolytic anemia and thrombocytopenia. Primary glomerulonephritis with 




Procollagen C-endopeptidase enhancer 
 
Fibrillar collagen types I-III are synthesized as precursor molecules known as procollagens. These precursors contain 
amino- and carboxyl-terminal peptide extensions known as N- and C-propeptides, respectively, which are cleaved, 
upon secretion of procollagen from the cell, to yield the mature triple helical, highly structured fibrils. This gene encodes 








Integrin, alpha V 
 
This gene encodes a protein that is a member of the integrin superfamily. Integrins are heterodimeric integral 
membrane proteins composed of an alpha chain and a beta chain. This protein undergoes post-translational cleavage 
to yield disulfide-linked heavy and light chains that combine with multiple integrin beta chains to form different integrins. 
This protein has been shown to heterodimerize with beta 1, beta 3, beta 5, beta 6, and beta 8; the heterodimer of alpha 
v and beta 3 is the Vitronectin receptor. This protein interacts with several extracellular matrix proteins to mediate cell 
adhesion and may play a role in cell migration. It is proposed that this protein may regulate angiogenesis and cancer 
progression. Alternative splicing results in multiple transcript variants that encode different protein isoforms. Note that 




TIMP metallopeptidase inhibitor 3 
 
This gene belongs to the TIMP gene family. The proteins encoded by this gene family are inhibitors of the matrix 
metalloproteinases, a group of peptidases involved in degradation of the extracellular matrix (ECM). Expression of this 
gene is induced in response to mitogenic stimulation and this netrin domain-containing protein is localized to the ECM. 




Chloride intracellular channel 5 
 
This gene encodes a member of the chloride intracellular channel (CLIC) family of chloride ion channels. The encoded 
protein associates with actin-based cytoskeletal structures and may play a role in multiple processes including hair cell 
stereocilia formation, myoblast proliferation and glomerular podocyte and endothelial cell maintenance. Alternatively 






This gene encodes a member of the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) and 
ADAMTS-like protein family. Members of the family share several distinct protein modules, including a propeptide 
region, a metalloproteinase domain, a disintegrin-like domain, and a thrombospondin type 1 (TS) motif. Individual 
members of this family differ in the number of C-terminal TS motifs, and some have unique C-terminal domains. The 
protein encoded by this gene lacks the protease domain, and is therefore of a member of the the ADAMTS-like protein 
subfamily. It is a secreted glycoprotein that binds the cell surface and extracellular matrix; it also interacts with latent 







 Gene$ Function! p$value!
SEMA3A$
Sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3A 
 
This secreted protein can function as either a chemorepulsive agent, inhibiting axonal outgrowth, or as a 
chemoattractive agent, stimulating the growth of apical dendrites. In both cases, the protein is vital for normal neuronal 
pattern development. Increased expression of this protein is associated with schizophrenia and is seen in a variety of 






The protein encoded by this gene is a member of the EGF family of growth factors. It is synthesized primarily as a 
transmembrane precursor, which is then processed to mature molecule by proteolytic events. This protein is a ligand 




Cytokine receptor-like factor 1 
 
This gene encodes a member of the cytokine type I receptor family. The protein forms a secreted complex with 
cardiotrophin-like cytokine factor 1 and acts on cells expressing ciliary neurotrophic factor receptors. The complex can 





Cartilage acidic protein 1 
 
gene encodes a glycosylated extracellular matrix protein that is found in the interterritorial matrix of articular deep zone 
cartilage. This protein is used as a marker to distinguish chondrocytes from osteoblasts and mesenchymal stem cells in 
culture. The presence of FG-GAP motifs and an RGD integrin-binding motif suggests that this protein may be involved 
in cell-cell or cell-matrix interactions. Copy number alterations in this gene have been observed in neurofibromatosis 




ERBB receptor feedback inhibitor 1 
 
ERRFI1 is a cytoplasmic protein whose expression is upregulated with cell growth. It shares significant homology with 






 Gene$ Function p$value!
NDUFA4L2$
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4-like 2 
 
an enzyme of the respiratory chains of myriad organisms from bacteria to humans. It catalyzes the transfer 
ofelectrons from NADH to coenzyme Q10 (CoQ10) and, in eukaryotes, it is located in the 






Adenylate kinase 1 
 
Adenylate kinase is an enzyme involved in regulating the adenine nucleotide composition within a cell by catalyzing the 
reversible transfer of phosphate group among adinine nucleotides. Three isozymes of adenylate kinase have been 
identified in vertebrates, adenylate isozyme 1 (AK1), 2 (AK2) and 3 (AK3). AK1 is found in the cytosol of skeletal 
muscle, brain and erythrocytes, whereas AK2 and AK3 are found in the mitochondria of other tissues including liver 
and heart. AK1 was identified because of its association with a rare genetic disorder causing nonspherocytic hemolytic 





Glutamine-fructose-6-phosphate transaminase 2 
is an enzyme that catalyzes the chemical reaction 
L-glutamine + D-fructose 6-phosphate  L-glutamate + D-glucosamine 6-phosphate 
Thus, the two substrates of this enzyme are L-glutamine and D-fructose 6-phosphate, whereas its two products are L-
glutamate and D-glucosamine 6-phosphate. 




G protein-coupled receptor 64  
 
GPR64 is significantly overexpressed in the Wnt signaling-dependent subgroup of medulloblastomas as well as in 









Netrins are a class of proteins involved in axon guidance. 
ns!
ZNF385B$
Zinc finger protein 385B 
 




Scavenger receptor class A, member 3 
 
This gene encodes a macrophage scavenger receptor-like protein. This protein has been shown to deplete reactive 
oxygen species, and thus play an important role in protecting cells from oxidative stress. The expression of this gene is 




Heparin-binding EGF-like growth factor 
 
HB-EGF-like growth factor is synthesized as a membrane-anchored mitogenic andchemotactic glycoprotein. An 
epidermal growth factor produced by monocytes and macrophages, due to an affinity for heparin is termed HB-EGF. It 






This gene encodes a protein which induces ectopic bone formation in conjunction with transforming growth factor beta. 




Somatomedin B and thrombospondin, type 1 domain containing 
 





Paired-like homeodomain 1  
 
Transcriptional regulator involved in basal and hormone-regulated activity of prolactin 
ns!
